Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 5/20 | 0.35 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | CA9 | Q16790 | 5/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL4507282 | 0.97 | TSHR (0.82) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL19193 | 0.94 | — | — | |
| SCHEMBL21064874 | 0.94 | TSHR (1.00) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL4431010 | 0.90 | TSHR (0.93) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL3495565 | 0.90 | — | — | |
| Methyl Alcohol SCHEMBL584909 | 0.90 | — | — | |
| Ammonia Solution, Strong SCHEMBL5086843 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL2107550 | 0.90 | — | — | |
| SCHEMBL1278490 | 0.90 | — | — | |
| Water SCHEMBL1289230 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717063-B | Preparation and purification method of tulobuterol | 北京泰德制药股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-115368245-A | Preparation method of (1R, 2S) - (3, 4-difluorophenyl) cyclopropylamine hydrochloride crystal form | 上海医药工业研究院 | 2022-11-22 | — | — | CN | claimed |
| CN-111902406-B | Medicinal salt and crystal form of aza-bicyclyl substituted triazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20220177455-A1 | CRYSTAL FORMS OF A PYRIDAZINONE TRPC INHIBITOR | GOLDFINCH BIO, INC. | 2022-06-09 | — | — | US | claimed |
| CN-112441881-B | Device and method for separating isopropanol-isopropyl acetate mixture | 汇智工程科技股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-113717063-A | Preparation and purification method of tulobuterol | 北京泰德制药股份有限公司 | 2021-11-30 | — | — | CN | claimed |
| US-20210300930-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | PTC THERAPEUTICS MP, INC. | 2021-09-30 | — | — | US | claimed |
| US-11072614-B2 | Polymorphs of sepiapterin and salts thereof | PTC THERAPEUTICS MP, INC. (US) | 2021-07-27 | — | — | US | claimed |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2021-06-24 | — | — | US | claimed |
| EP-3808745-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-04-21 | — | — | EP | claimed |
| CN-112441881-A | Device and method for separating isopropanol-isopropyl acetate mixture | 汇智工程科技股份有限公司 | 2021-03-05 | — | — | CN | claimed |
| CN-111902406-A | Medicinal salt and crystal form of aza-bicyclyl substituted triazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-11-06 | — | — | CN | claimed |
| CN-107501042-B | Method for preparing isopropanol by hydrolyzing isopropyl acetate | 惠州宇新化工有限责任公司 | 2020-08-11 | — | — | CN | claimed |
| US-20190308975-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | CENSA PHARMACEUTICALS INC. (US) | 2019-10-10 | — | — | US | claimed |
| EP-3548497-A1 | POLYMOPRHS OF SEPIAPTERIN AND SALTS THEREOF | Censa Pharmaceuticals Inc. (US) | 2019-10-09 | — | — | EP | claimed |
| CN-110156590-A | A method of spirit of vinegar is recycled based on extraction/azeotropic distillation coupling technique | 华东理工大学 | 2019-08-23 | — | — | CN | claimed |
| WO-2018102315-A1 | POLYMOPRHS OF SEPIAPTERIN AND SALTS THEREOF | CENSA PHARMACEUTICALS INC. (US) | 2018-06-07 | — | — | WO | claimed |
| CN-107501042-A | A kind of method that isopropanol is prepared by isopropyl acetate ester hydrolysis | 惠州宇新化工有限责任公司 | 2017-12-22 | — | — | CN | claimed |
| CN-105061147-A | Batch distillation process for separating isopropanol-isopropyl acetate azeotrope through mixed extraction agent | UNIV JINAN | 2015-11-18 | — | — | CN | claimed |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | CURIA GLOBAL, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3908587-B1 | METHOD FOR SYNTHESIS OF DIAZABICYCLO[6.2.0]DECANE RELATED COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2024-05-22 | — | — | EP | disclosed |
| EP-3733642-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-110305118-B | Synthetic method suitable for industrial production of enggliflozin | 四川科伦药物研究院有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-115368245-B | Preparation method of hydrochloride crystal form of (1R, 2S) - (3, 4-difluorophenyl) cyclopropylamine | 上海医药工业研究院 | 2024-03-22 | — | — | CN | disclosed |
| US-20240043426-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | PTC THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-3848375-B1 | METHODS OF PREPARING INTERMEDIATES FOR TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| EP-4281069-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | NFlection Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11773097-B2 | Polymorphs of sepiapterin and salts thereof | PTC THERAPEUTICS MP, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-113717063-B | Preparation and purification method of tulobuterol | 北京泰德制药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-112094856-B | Transaminase mutant and application thereof in sitagliptin synthesis | 国药集团威奇达药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-115960080-A | Polycyclic compound and application thereof as ghrelin receptor agonist | 南京知和医药科技有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-111362824-B | Process for the preparation of 2- (aminomethyl) -N, N-diethyl-1-phenylcyclopropanecarboxamide and salts thereof | 四川科瑞德制药股份有限公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2022256550-A1 | CRYSTALLINE FORMS OF AN ADENOSINE A2B RECEPTOR ANTAGONIST | TEON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-115368245-A | Preparation method of (1R, 2S) - (3, 4-difluorophenyl) cyclopropylamine hydrochloride crystal form | 上海医药工业研究院 | 2022-11-22 | — | — | CN | disclosed |
| CN-111902406-B | Medicinal salt and crystal form of aza-bicyclyl substituted triazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115043840-A | Methods for preparing TOLL-like receptor modulators | 吉利德科学公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-107074860-B | Methods for preparing TOLL-like receptor modulators | 吉利德科学公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220177455-A1 | CRYSTAL FORMS OF A PYRIDAZINONE TRPC INHIBITOR | GOLDFINCH BIO, INC. | 2022-06-09 | — | — | US | disclosed |
| CN-112441881-B | Device and method for separating isopropanol-isopropyl acetate mixture | 汇智工程科技股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112441881-B | Device and method for separating isopropanol-isopropyl acetate mixture | 汇智工程科技股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112441881-B | Device and method for separating isopropanol-isopropyl acetate mixture | 汇智工程科技股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-111819178-B | Crystal form of pyrazolo heteroaryl derivative hydrochloride and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-109824590-B | Preparation method of Lovatinib and salt thereof | 扬子江药业集团有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114105847-A | Refining method of Vernakalant hydrochloride | 上海旭东海普药业有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-113717063-A | Preparation and purification method of tulobuterol | 北京泰德制药股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3908587-A1 | METHOD FOR SYNTHESIS OF DIAZABICYCLO[6.2.0]DECANE RELATED COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2021-11-17 | — | — | EP | disclosed |
| CN-113661166-A | Process for the synthesis of diazabicyclo [6.2.0] decane-related compounds | 卫材R&D管理有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210300930-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | PTC THERAPEUTICS MP, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11130760-B2 | Polymorphic form of sepiapterin | PTC THERAPEUTICS MP, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210251981-A1 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11072614-B2 | Polymorphs of sepiapterin and salts thereof | PTC THERAPEUTICS MP, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| EP-3848375-A1 | METHODS OF PREPARING INTERMEDIATES FOR TOLL-LIKE RECEPTOR MODULATORS | Gilead Sciences, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2021-06-24 | — | — | US | disclosed |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2021-06-17 | — | — | US | disclosed |
| CN-107188800-B | Steviol crystal in crystal form A, and preparation method and application thereof | 江南大学 | 2021-05-28 | — | — | CN | disclosed |
| EP-3808745-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10959999-B2 | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2021-03-30 | — | — | US | disclosed |
| CN-112441881-A | Device and method for separating isopropanol-isopropyl acetate mixture | 汇智工程科技股份有限公司 | 2021-03-05 | — | — | CN | disclosed |
| CN-112441881-A | Device and method for separating isopropanol-isopropyl acetate mixture | 汇智工程科技股份有限公司 | 2021-03-05 | — | — | CN | disclosed |
| CN-112441881-A | Device and method for separating isopropanol-isopropyl acetate mixture | 汇智工程科技股份有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-20210024461-A1 | (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-28 | — | — | US | disclosed |
| CN-112094856-A | Transaminase mutant and application thereof in sitagliptin synthesis | 国药集团威奇达药业有限公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-107698569-B | Bipyrazole derivatives as JAK inhibitors | 因赛特公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3461828-B1 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| CN-111902406-A | Medicinal salt and crystal form of aza-bicyclyl substituted triazole derivative and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-3733642-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10815196-B2 | (S)-CSA salt of S-ketamine, (R)-CSA salt of S-ketamine and processes for the preparation of S-ketamine | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| CN-111819178-A | Crystal form of pyrazolo heteroaryl derivative hydrochloride and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-108430990-B | Crystal of quinazoline derivative and method for producing same | 山东轩竹医药科技有限公司 | 2020-08-25 | — | — | CN | disclosed |
| CN-107501042-B | Method for preparing isopropanol by hydrolyzing isopropyl acetate | 惠州宇新化工有限责任公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020146568-A1 | METHOD FOR SYNTHESIS OF DIAZABICYCLO[6.2.0]DECANE RELATED COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-16 | — | — | WO | disclosed |
| CN-111410672-A | Rebaudioside crystal in crystal form B, preparation method and application | 江南大学 | 2020-07-14 | — | — | CN | disclosed |
| CN-111362824-A | Process for the preparation of 2- (aminomethyl) -N, N-diethyl-1-phenylcyclopropanecarboxamide and salts thereof | 四川科瑞德制药股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| US-10689359-B2 | Crystals of quinazoline derivative and preparation method therefor | Xuanzhu Pharma Co., Ltd. (CN) | 2020-06-23 | — | — | US | disclosed |
| US-20200188387-A1 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3395811-B1 | CRYSTALS OF QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | XUANZHU PHARMA CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| CN-111032628-A | Process for preparing tert-butyl (S) -4, 5-diamino-5-oxovalerate | 细胞基因公司 | 2020-04-17 | — | — | CN | disclosed |
| EP-3456707-B1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-2817400-B1 | NATURAL OIL BASED GELS, APPLICATIONS AND METHODS OF PREPARATION | ETHOX CHEMICALS LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2020015321-A1 | METHOD AND DEVICE FOR SEPARATING ISOPROPANOL | 惠州宇新化工有限责任公司 | 2020-01-23 | — | — | WO | disclosed |
| US-20190308975-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | CENSA PHARMACEUTICALS INC. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3548497-A1 | POLYMOPRHS OF SEPIAPTERIN AND SALTS THEREOF | Censa Pharmaceuticals Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3548487-A1 | POLYMORPHIC FORM OF SEPIAPTERIN | Censa Pharmaceuticals Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| CN-110312721-A | The polymorph of sepiapterin | 显莎制药公司 | 2019-10-08 | — | — | CN | disclosed |
| CN-110305118-A | A kind of synthetic method that suitable industrial production En Gelie is net | 四川科伦药物研究院有限公司 | 2019-10-08 | — | — | CN | disclosed |
| EP-2914574-B1 | NEW PROCESS | CAMBREX KARLSKOGA AB (SE) | 2019-10-02 | — | — | EP | disclosed |
| CN-110248948-A | Polymorphs of sepiapterin and salts thereof | 显莎制药公司 | 2019-09-17 | — | — | CN | disclosed |
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| EP-3461828-A2 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES, INC. (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3456707-A1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BioElectron Technology Corporation (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-2970821-B1 | BIO-BASED DISPERSANTS | ETHOX CHEMICALS LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| CN-109280029-A | A kind of preparation method of hydroxychloroquine sulfate | 上海应用技术大学 | 2019-01-29 | — | — | CN | disclosed |
| US-20190002434-A1 | CRYSTALS OF QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | Xuanzhu Pharma Co., Ltd. (CN) | 2019-01-03 | — | — | US | disclosed |
| US-10167251-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| CN-108947774-A | A kind of method and device of separating isopropanol | 惠州宇新化工有限责任公司 | 2018-12-07 | — | — | CN | disclosed |
| EP-3194402-B1 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-3395811-A1 | CRYSTALS OF QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | Xuanzhu Pharma Co., Ltd. (CN) | 2018-10-31 | — | — | EP | disclosed |
| EP-3018122-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180282266-A1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-04 | — | — | US | disclosed |
| CN-108430990-A | Crystal of quinazoline derivant and preparation method thereof | 山东轩竹医药科技有限公司 | 2018-08-21 | — | — | CN | disclosed |
| WO-2018102314-A1 | POLYMORPHIC FORM OF SEPIAPTERIN | CENSA PHARMACEUTICALS INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102315-A1 | POLYMOPRHS OF SEPIAPTERIN AND SALTS THEREOF | CENSA PHARMACEUTICALS INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| CN-107556350-A | Rubusoside crystal, its preparation method, food compositions and application with crystal formation A forms | 江南大学 | 2018-01-09 | — | — | CN | disclosed |
| CN-107501042-A | A kind of method that isopropanol is prepared by isopropyl acetate ester hydrolysis | 惠州宇新化工有限责任公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-103965059-B | The method that one kind prepares (1R, 2S) 2 (3,4 difluorophenyl) cyclopropylamine | 上海科胜药物研发有限公司 | 2017-12-22 | — | — | CN | disclosed |
| US-20170313649-A1 | 4-(pQUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2017-11-02 | — | — | US | disclosed |
| US-9771317-B2 | Process for preparing lacosamide and related compounds | CAMBREX KARLSKOGA AB (SE) | 2017-09-26 | — | — | US | disclosed |
| EP-3194402-A1 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | Gilead Sciences, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| CN-104788361-B | The synthetic method of the formic acid derivates of 5 azaspiros [2.4] heptane 6 | 杭州科巢生物科技有限公司 | 2017-06-30 | — | — | CN | disclosed |
| US-9573952-B2 | Methods of preparing toll-like receptor modulators | GILEAD SCIENCES, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9546132-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160332962-A1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-17 | — | — | US | disclosed |
| US-9376647-B2 | Natural oil based gels, applications and methods of preparation | ETHOX CHEMICALS, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| CN-104163769-B | A kind of preparation method of chlorination propionyl-L-carnitine | 海南霞迪药业有限公司 | 2016-06-15 | — | — | CN | disclosed |
| EP-3018122-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | Edison Pharmaceuticals, Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| WO-2016044183-A1 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075707-A1 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES, INC. | 2016-03-17 | — | — | US | disclosed |
| US-20160075638-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2016-03-17 | — | — | US | disclosed |
| EP-2989080-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED 3-HYDROXYMETHYLPIPERIDINE | Reuter Chemische Apparatebau KG (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2970821-A2 | BIO-BASED DISPERSANTS | Ethox Chemicals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2220030-B1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2948432-A1 | PROCESS FOR MAKING IVABRADINE | Synthon BV (NL) | 2015-12-02 | — | — | EP | disclosed |
| CN-105061148-A | Distillation separation method used for isopropanol-isopropyl acetate azeotrope and based on mixed solvent serving as extracting agent | UNIV JINAN | 2015-11-18 | — | — | CN | disclosed |
| CN-105061147-A | Batch distillation process for separating isopropanol-isopropyl acetate azeotrope through mixed extraction agent | UNIV JINAN | 2015-11-18 | — | — | CN | disclosed |
| CN-105061147-A | Batch distillation process for separating isopropanol-isopropyl acetate azeotrope through mixed extraction agent | UNIV JINAN | 2015-11-18 | — | — | CN | disclosed |
| CN-105061147-A | Batch distillation process for separating isopropanol-isopropyl acetate azeotrope through mixed extraction agent | UNIV JINAN | 2015-11-18 | — | — | CN | disclosed |
| CN-105061148-A | Distillation separation method used for isopropanol-isopropyl acetate azeotrope and based on mixed solvent serving as extracting agent | UNIV JINAN | 2015-11-18 | — | — | CN | disclosed |
| US-9181280-B2 | Factor VIIa inhibitor | PHARMACYCLICS LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9169196-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150299105-A1 | NEW PROCESS | CAMBREX KARLSKOGA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| EP-2914574-A2 | NEW PROCESS | Cambrex Karlskoga Ab (SE) | 2015-09-09 | — | — | EP | disclosed |
| CN-104788361-A | Synthetic method for 5-azaspiro[2.4]heptane-6-formic acid derivative | HANGZHOU CHEMINSPIRE TECHNOLOGIES CO LTD | 2015-07-22 | — | — | CN | disclosed |
| EP-2817400-A2 | NATURAL OIL BASED GELS, APPLICATIONS AND METHODS OF PREPARATION | Ethox Chemicals Inc. (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014173855-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED 3-HYDROXYMETHYLPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014145972-A2 | BIO-BASED DISPERSANTS | ETHOX CHEMICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275370-A1 | BIO-BASED DISPERSANTS | ETHOX CHEMICALS, LLC | 2014-09-18 | — | — | US | disclosed |
| US-20140243549-A1 | NATURAL OIL BASED GELS, APPLICATIONS AND METHODS OF PREPARATION | FIRST NATIONAL BANK OF PENNSYLVANIA | 2014-08-28 | — | — | US | disclosed |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014114341-A1 | PROCESS FOR MAKING IVABRADINE | SYNTHON BV (NL) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014068333-A2 | NEW PROCESS | CAMBREX KARLSKOGA AB (SE) | 2014-05-08 | — | — | WO | disclosed |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2013-10-31 | — | — | US | disclosed |
| WO-2013126916-A2 | NATURAL OIL BASED GELS, APPLICATIONS AND METHODS OF PREPARATION | ETHOX CHEMICALS, INC. (US) | 2013-08-29 | — | — | WO | disclosed |
| US-8519001-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8415328-B2 | Factor VIIa inhibitor | PHARMACYCLICS, INC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-8129413-B2 | Crystalline forms of MC4R agonist and process for synthesis | MERCK SHARP & DOHME CORP. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20120029216-A1 | SCALABLE SYNTHETIC PROCESS FOR MAKING TERAMEPROCOL | ERIMOS PHARMACEUTICALS LLC (US) | 2012-02-02 | — | — | US | disclosed |
| US-8007657-B2 | Treating with esters of glycolic, lactic, gluconic acids; methylic, ethylic and isobutylic esters of glutaric, succinic and adipic acids; and a hydrogenated sugar | ROQUETTE FRERES (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20110207939-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-7968746-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2318347-A2 | SCALABLE SYNTHETIC PROCESS FOR MAKING TERAMEPROCOL | Erimos Pharmaceuticals LLC (US) | 2011-05-11 | — | — | EP | disclosed |
| EP-2298775-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7910573-B2 | Methanol and ethanol solvates; breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-03-22 | — | — | US | disclosed |
| EP-2295437-A1 | Diazabicyclic central nervous system active agents | Abbott Laboratories (US) | 2011-03-16 | — | — | EP | disclosed |
| WO-2010014936-A2 | SCALABLE SYNTHETIC PROCESS FOR MAKING TERAMEPROCOL | ERIMOS PHARMACEUTICALS LLC (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090247581-A1 | Organic Compounds | PRASHAD MAHAVIR | 2009-10-01 | — | — | US | disclosed |
| US-20090233967-A1 | Crystalline forms of mc4r agonist and process for synthesis | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| US-7534543-B2 | Texture control of thin film layers prepared via laser induced thermal imaging | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20080300410-A1 | Organic Compounds | PRASHAD MAHAVIR | 2008-12-04 | — | — | US | disclosed |
| EP-1994001-A2 | BENZENESZKFIBATE SALTS AND THEIR USE AS INTERMEDIATES FOR THE SYNTHESIS OF 2-[2-(1-ALKYL-2-PIPERIDYL)ETHYL] CINNAMANILIDES | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20080275250-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1951670-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-08-06 | — | — | EP | disclosed |
| US-7399881-B1 | Transesterification process of methyl acetate | NATIONAL TAIWAN UNIVERSITY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-20080161595-A1 | TRANSESTERIFICATION PROCESS OF METHYL ACETATE | NATIONAL TAIWAN UNIVERSITY (TW) | 2008-07-03 | — | — | US | disclosed |
| US-20080146477-A1 | Preparation and Treating of Bituminous Compositions | ROQUETTE FRERES (FR) | 2008-06-19 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080085875-A1 | CRYSTALLINE FORMS OF 11SS-(4-ACETYLPHENYL)-20,20,21,21,21-PENTAFLUORO-17-HYDROXY-19-NOR-17A-PREGNA-4,9-DIEN-3-ONE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| WO-2007111706-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007111705-A2 | BENZENESZKFIBATE SALTS AND THEIR USE AS INTERMEDIATES FOR THE SYNTHESIS OF 2-[2-(1-ALKYL-2-PIPERIDYL)ETHYL] CINNAMANILIDES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-7189856-B2 | Central nervous system disorders; vision defects; antiproliferative agents | SHAPIRO GIDEON | 2007-03-13 | — | — | US | disclosed |
| US-7186863-B2 | Sertraline compositions | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2007002462-A2 | CRYSTALLINE FORMS OF MC4R AGONIST AND PROCESS FOR SYNTHESIS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050287315-A1 | thermal transfer donor element is provided which includes a support, light-to-heat conversion layer, interlayer, and thermal transfer layer; useful in making colored images including applications such as color proofs, color filter elements, and organic light emitting displays | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-11-10 | — | — | US | disclosed |
| EP-1484330-B1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO KG (DE) | 2005-10-26 | — | — | EP | disclosed |
| CN-1642554-A | Morpholinium urea derivative benzenesulfonates as CCR-3 antagonists for the treatment of inflammation | GLAXO GROUP LTD (GB) | 2005-07-20 | — | — | CN | disclosed |
| US-6919342-B2 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2005-07-19 | — | — | US | disclosed |
| EP-1535923-A1 | Synthesis of acyclic nucleoside derivatives | Medivir Aktiebolag (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-6878844-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-04-12 | — | — | US | disclosed |
| US-20050014829-A1 | Sertraline compositions | TRANSFORM PHARMACEUTICALS, INC. | 2005-01-20 | — | — | US | disclosed |
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004108706-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1484330-A1 | Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-02-05 | — | — | US | disclosed |
| US-20030191134-A1 | Non-peptide somatostatin receptor ligands | SHAPIRO GIDEON (US) | 2003-10-09 | — | — | US | disclosed |
| US-6613936-B1 | Herpes and retroviral infections; diester derivatives of H2G bearing specific combinations of an amino acid ester and a fatty acid ester, improved oral bioavailability; 9-(2-(butyryloxymethyl)-4-(L-isoleucyloxy)butyl)guanine | MEDIVIR AB (SE) | 2003-09-02 | — | — | US | disclosed |
| WO-2003057214-A1 | IMIDAZOLIDIN-2,4-DIONE DERIVATIVES AS NON-PEPTIDE SOMATOSTATIN RECEPTOR LIGANDS | SOMATOCOR PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| EP-1284976-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1131323-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 2001-09-12 | — | — | EP | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| WO-2000008025-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-02-17 | — | — | WO | disclosed |
| US-5861508-A | PRODUCTION OF A SALT OF 7-(2-(2-AMINOTHIAZOL4-YL)-2-(Z)-HYDROXIMINOACETAMIDO)-3-N,N-DI METHYLCARBAMOYLOXYMETHYL-3-CEPHEM-4-CARBOXYLIC ACID (ISOPROPOXYCARBONYLOXY)ETHYLESTER P-TOLUENE-SULPHONIC ACID | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1999-01-19 | — | — | US | disclosed |
| US-5659030-A | ANTIBIOTIC DRUG IN CRYSTAL FORM | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1997-08-19 | — | — | US | disclosed |
| EP-0513771-B1 | Process for preparing free flowing spheroidal nitrocellulose particles | AQUALON CO (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0687676-A1 | Purification of a cephalosporin salt | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 1995-12-20 | — | — | EP | disclosed |
| US-5455248-A | Treatment or prevention of neurodegenerative disorders or neurotoxic injuries; binding to PCP receptors | STERLING WINTHROP INC. (US) | 1995-10-03 | — | — | US | disclosed |
| US-5434159-A | Neurodegenerative disorders | STERLING WINTHROP INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0513771-A2 | Free flowing spheroidal nitrocellulose particles and process for the same | AQUALON COMPANY (US) | 1992-11-19 | — | — | EP | disclosed |
| US-5144020-A | Improved solubility, slower burn rate | AQUALON COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0178947-B1 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4812452-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-14 | — | — | US | disclosed |
| US-4812451-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-14 | — | — | US | disclosed |
| US-4810703-A | ANTIARRHYTHMIA | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| US-4751246-A | ALPHA(AMINOALKYL)-4-HYDROXY-3-(ALKYLSULFINYL) BENZENEMETHANOL AND 2-(4-HYDROXY-3-(ALKYLSULFINYL) PHENYL)ETHYLAMINE-HYPOTENSIVE AGENTS | STERLING DRUG INC. (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0124265-B1 | PROCESS FOR FORMING PATTERN WITH NEGATIVE RESIST | Oki Electric Industry Company, Limited (JP) | 1987-10-07 | — | — | EP | disclosed |
| US-4698137-A | AMIDE EXTRACTION AGENT | BERG LLOYD | 1987-10-06 | — | — | US | disclosed |
| US-4695589-A | HYPOTENSIVE AGENTS | STERLING DRUG INC. (US) | 1987-09-22 | — | — | US | disclosed |
| US-4675080-A | PHTHALATES | BERG LLOYD | 1987-06-23 | — | — | US | disclosed |
| US-4594343-A | FOR DEEP FAT FRYING VAT OIL; REMOVING CONTAMINANTS; RESTAURANTS | A.H. ROBINS COMPANY, INCORPORATED, A DE CORP. | 1986-06-10 | — | — | US | disclosed |
| EP-0178947-A2 | 1-[(Aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-alpha,alpha-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-04-23 | — | — | EP | disclosed |
| US-4582931-A | OXAZOLINE DEUTERATION | MERCK & CO., INC. (US) | 1986-04-15 | — | — | US | disclosed |
| US-4499101-A | HISTAMINE H2-ANTAGONISTS; ANTISECRETORY ANTIINFLAMMOATORY AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-02-12 | — | — | US | disclosed |
| US-4452816-A | HYPOTENSIVE AND ANTIARRHYTHMIA AGENTS | STERLING DRUG INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4388319-A | ANTIHISTAMINES, ANTISECRETORY, ANTIINFLAMMATORY, HYPOTENSIVE AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1983-06-14 | — | — | US | disclosed |
| US-4374149-A | HYPOTENSIVE AGENT AND VASODILATOR | STERLING DRUG INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4307101-A | ANTIHISTAMINES AND ANTISECRETORY AGENTS OF THE THIOUREA OR UREA DERIVATIVES 5,6,7,8-TETRAHYDROIMIDAZO(1,5A)PYRIDINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-12-22 | — | — | US | disclosed |
| US-4293697-A | ANTIHISTAMINES | SMITH, KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-10-06 | — | — | US | disclosed |
| US-4271169-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-06-02 | — | — | US | disclosed |
| US-4230865-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-28 | — | — | US | disclosed |
| US-4226874-A | ANTIHISTAMINES, ANTISECRETORY AGENTS, GASTRIC JUICE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-10-07 | — | — | US | disclosed |
| US-4221802-A | Pharmacologically active guanidine compounds for inhibiting H-2 histamine receptors | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-09-09 | — | — | US | disclosed |
| US-4215125-A | H-2 HISTAMINE RECEPTOR INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-29 | — | — | US | disclosed |
| US-4154844-A | ANTIHISTAMINE, GASTRIC JUICE ANTISECRETORY AGENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
| US-4152443-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-01 | — | — | US | disclosed |
| US-4151288-A | ANTHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-04-24 | — | — | US | disclosed |
| US-4137234-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-01-30 | — | — | US | disclosed |
| US-4112104-A | UREA, THIOUREA OR GUANIDINE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-09-05 | — | — | US | disclosed |
| US-4104382-A | (((THIAZOLYL-, ISOTHIAZOLYL- OR PYRIDYLALKYL)THIO)ALKYL)GUANIDINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-08-01 | — | — | US | disclosed |
| US-4070475-A | THIOALKYL-, AMINOALKYL-, AND OXYALKYL- SUBSTITUTED GUANIDINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1978-01-24 | — | — | US | disclosed |
| US-4025527-A | H-2 HISTAMINE RECEPTOR INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-24 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-4018931-A | INHIBITION OF H-2 HISTAMINE RECEPTORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-04-19 | — | — | US | disclosed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | disclosed |
| US-3950353-A | HISTAMINE INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
| US-3950353-A | HISTAMINE INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024461-A1 | (S)-CSA Salt Of S-Ketamine, (R)-CSA Salt Of S-Ketamine And Processes For The Preparation Of S-Ketamine | STS, SRR, SRM | TSHR 4759/4885CHRM2 2928/4885CHRM4 2314/4885 |
| US-20240043426-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | SPR, PAH, SORD | TSHR 4788/4885CHRM2 3678/4885CHRM4 3394/4885 |
| US-20050014829-A1 | Sertraline compositions | SUCNR1, TST, SORD | TSHR 96/4885CHRM2 2003/4885CHRM4 2633/4885 |
| US-20160075707-A1 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS | TLR3, TLR4, TLR6 | TSHR 700/4885CHRM2 3536/4885CHRM4 1789/4885 |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | TSHR 2636/4885CHRM2 122/4885CHRM4 103/4885 |
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TSHR 2738/4885CHRM2 3212/4885CHRM4 3077/4885 |
| US-20150299105-A1 | NEW PROCESS | SLC6A11, SLC6A1, SCN11A | TSHR 4395/4885CHRM2 1835/4885CHRM4 3201/4885 |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TSHR 2679/4885CHRM2 3127/4885CHRM4 3016/4885 |
| US-20240228480-A1 | PROCESSES FOR PREPARING PYRROLOPYRIDINE-ANILINE COMPOUNDS | ADH1C, SIK1, PKN2 | TSHR 4723/4885CHRM2 2738/4885CHRM4 4053/4885 |
| US-20210251981-A1 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | SLC10A1, CYP7A1, NR1H4 | TSHR 4197/4885CHRM2 4021/4885CHRM4 4200/4885 |
| US-20180282266-A1 | (S)-CSA SALT OF S-KETAMINE, (R)-CSA SALT OF S-KETAMINE AND PROCESSES FOR THE PREPARATION OF S-KETAMINE | STS, SRR, SRM | TSHR 4759/4885CHRM2 2928/4885CHRM4 2314/4885 |
| US-20210300930-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | SPR, PAH, SORD | TSHR 4788/4885CHRM2 3678/4885CHRM4 3394/4885 |
| US-20160075638-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TSHR 2679/4885CHRM2 3127/4885CHRM4 3016/4885 |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | TSHR 2679/4885CHRM2 3127/4885CHRM4 3016/4885 |
| US-11072614-B2 | Polymorphs of sepiapterin and salts thereof | SPR, PAH, SORD | TSHR 4788/4885CHRM2 3678/4885CHRM4 3394/4885 |
| US-20040259882-A1 | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | DRD3, SLC6A3, DRD2 | TSHR 57/4885CHRM2 182/4885CHRM4 278/4885 |
| US-20190002434-A1 | CRYSTALS OF QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEE2, WEE1, UGT1A7 | TSHR 3710/4885CHRM2 1973/4885CHRM4 2495/4885 |
| US-20110207939-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | TSHR 2415/4885CHRM2 4846/4885CHRM4 4851/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | TSHR 2636/4885CHRM2 122/4885CHRM4 103/4885 |
| US-11130760-B2 | Polymorphic form of sepiapterin | SPR, SHMT1, SHMT2 | TSHR 4537/4885CHRM2 3434/4885CHRM4 3119/4885 |
| US-20120122934-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TSHR 2679/4885CHRM2 3127/4885CHRM4 3016/4885 |
| US-20220177455-A1 | CRYSTAL FORMS OF A PYRIDAZINONE TRPC INHIBITOR | TRPC1, TPH1, TRPC3 | TSHR 1082/4885CHRM2 1335/4885CHRM4 1381/4885 |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TSHR 2679/4885CHRM2 3127/4885CHRM4 3016/4885 |
| US-20200188387-A1 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | SLC10A1, CYP7A1, NR1H4 | TSHR 4197/4885CHRM2 4021/4885CHRM4 4200/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | TSHR 2729/4885CHRM2 108/4885CHRM4 91/4885 |
| US-10959999-B2 | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | SLC10A1, CYP7A1, NR1H4 | TSHR 4197/4885CHRM2 4021/4885CHRM4 4200/4885 |
| US-20080300410-A1 | Organic Compounds | C1S, C9, C1R | TSHR 2858/4885CHRM2 2257/4885CHRM4 2828/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | TSHR 2636/4885CHRM2 122/4885CHRM4 103/4885 |
| US-10815196-B2 | (S)-CSA salt of S-ketamine, (R)-CSA salt of S-ketamine and processes for the preparation of S-ketamine | STS, SRR, SRM | TSHR 4759/4885CHRM2 2928/4885CHRM4 2314/4885 |
| US-20040024214-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | TSHR 3700/4885CHRM2 3703/4885CHRM4 4459/4885 |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | TSHR 2679/4885CHRM2 3127/4885CHRM4 3016/4885 |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | TSHR 2415/4885CHRM2 4846/4885CHRM4 4851/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | TSHR 2729/4885CHRM2 108/4885CHRM4 91/4885 |
| US-20140275370-A1 | BIO-BASED DISPERSANTS | DBI, FABP1, FASN | TSHR 1812/4885CHRM2 3068/4885CHRM4 2984/4885 |
| US-10167251-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | TSHR 2786/4885CHRM2 3181/4885CHRM4 3030/4885 |
| US-20120029216-A1 | SCALABLE SYNTHETIC PROCESS FOR MAKING TERAMEPROCOL | PTGIS, PTGES, POR | TSHR 882/4885CHRM2 4641/4885CHRM4 3902/4885 |
| US-20090233967-A1 | Crystalline forms of mc4r agonist and process for synthesis | MC4R, MC3R, MC2R | TSHR 39/4885CHRM2 498/4885CHRM4 65/4885 |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | TSHR 903/4885CHRM2 3476/4885CHRM4 3300/4885 |
| US-20170313649-A1 | 4-(pQUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ECHS1 | TSHR 2470/4885CHRM2 3395/4885CHRM4 3421/4885 |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | TSHR 3700/4885CHRM2 3703/4885CHRM4 4459/4885 |
| US-20080275250-A1 | Factor Viia Inhibitor | F7, F9, F5 | TSHR 2334/4885CHRM2 4849/4885CHRM4 4852/4885 |
| US-11773097-B2 | Polymorphs of sepiapterin and salts thereof | SPR, PAH, SORD | TSHR 4788/4885CHRM2 3678/4885CHRM4 3394/4885 |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | ASNS, NUDT1, PNP | TSHR 2393/4885CHRM2 1835/4885CHRM4 3207/4885 |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | TSHR 2738/4885CHRM2 3212/4885CHRM4 3077/4885 |
| US-20080085875-A1 | CRYSTALLINE FORMS OF 11SS-(4-ACETYLPHENYL)-20,20,21,21,21-PENTAFLUORO-17-HYDROXY-19-NOR-17A-PREGNA-4,9-DIEN-3-ONE | HSD17B1, CYP17A1, HSD17B11 | TSHR 661/4885CHRM2 1465/4885CHRM4 697/4885 |
| US-10689359-B2 | Crystals of quinazoline derivative and preparation method therefor | WEE2, WEE1, UGT1A7 | TSHR 3785/4885CHRM2 1901/4885CHRM4 2562/4885 |
| US-20090247581-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO2B1 | TSHR 4215/4885CHRM2 3147/4885CHRM4 3162/4885 |
| US-20210188856-A1 | CRYSTAL FORM OF HYDROCHLORIDE OF PYRAZOLOHETEROARYL DERIVATIVE AND PREPARATION METHOD | CYP2F1, CYP7A1, CYP11B2 | TSHR 2375/4885CHRM2 2074/4885CHRM4 2774/4885 |
| US-20030191134-A1 | Non-peptide somatostatin receptor ligands | SSTR2, SSTR1, SSTR3 | TSHR 34/4885CHRM2 908/4885CHRM4 1035/4885 |
| US-20190308975-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | SPR, PAH, SORD | TSHR 4788/4885CHRM2 3678/4885CHRM4 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.